LUNGライブシグナル | Getagraph.comで利益を最大化

売る 108137 min ago

@ $14.55

発行日: 14 2月 2024 @ 23:30

リターン: -49.00%

前回のシグナル: 2月 13 - 23:30

前回のシグナル: 買う

リターン: 2.50 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:48):

Stats
本日の出来高	125 782
平均出来高	577 979
時価総額	285.95M
EPS	$0 ( 2024-02-21 )
次の収益日	( $-0.430 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.64
ATR14	$0.00500 (0.07%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-22	Rose Geoffrey Beran	Sell	1 184	Common Stock
2024-04-03	Joshi Mehul	Buy	0
2024-03-22	Rose Geoffrey Beran	Sell	1 184	Common Stock
2024-03-15	Williamson Steven S.	Buy	425 116	Employee Stock Option (right to buy)
2024-03-15	Williamson Steven S.	Buy	205 286	Common Stock

INSIDER POWER
77.49
Last 98 transactions
Buy: 1 710 475 \| Sell: 224 988

ボリューム相関

長: -0.23 (neutral)

短: -0.18 (neutral)

Signal:(27.803) Neutral

Pulmonx Corporation 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Pulmonx Corporation 相関 - 通貨/商品

-0.49
( neutral )

-0.40
( neutral )

0.00
( neutral )

-0.41
( neutral )

0.64
( weak )

0.44
( neutral )

Pulmonx Corporation 財務諸表

Annual	2023
収益:	$68.68M
総利益:	$50.35M (73.32 %)
EPS:	$-1.600

FY	2023
収益:	$68.68M
総利益:	$50.35M (73.32 %)
EPS:	$-1.600

FY	2022
収益:	$53.66M
総利益:	$39.87M (74.29 %)
EPS:	$-1.590

FY	2021
収益:	$48.42M
総利益:	$35.63M (73.59 %)
EPS:	$-1.350

Financial Reports:

No articles found.

Pulmonx Corporation

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.